Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Alteplase (Primary) ; Apixaban; Heparin
- Indications Pulmonary embolism
- Focus Therapeutic Use
- Acronyms SAFE-LYSE
Most Recent Events
- 26 Apr 2021 Status changed from suspended to discontinued.
- 08 Sep 2020 Planned End Date changed from 1 Apr 2022 to 5 Apr 2021.
- 08 Sep 2020 Status changed to suspended due to COVID-19 pandemic.